Throughout this medical market research, the publisher analyzed 13 neuromodulation device companies across the globe and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.
While this MedSuite report contains all of the Global Neuromodulation Devices market analysis, each of the market segments is also available as stand-alone MedCore reports. Additionally, this research includes a neuromodulation procedure volume analysis which can also be purchased as a separate report, MedPro.
Markets Covered
Global Neuromodulation Devices Market Insights
The growing global diabetes epidemic is largely attributed to developing countries adopting a Western diet and a more sedentary lifestyle. Gastroparesis cases caused by diabetes are the rise, driving the gastric electric stimulation market. Neuromodulation therapy is widely considered a second-line treatment, due to its invasiveness and upfront cost compared to pharmaceuticals. Price-sensitive nations with insufficient reimbursement policies will be slow to adopt this therapy.
Overall, the global neuromodulation device market was valued at nearly $4.4 billion in 2019. This is expected to increase over the forecast period at a CAGR of 7.6% to approach $7.3 billion.
While this MedSuite report contains all of the Global Neuromodulation Devices market analysis, each of the market segments is also available as stand-alone MedCore reports. Additionally, this research includes a neuromodulation procedure volume analysis which can also be purchased as a separate report, MedPro.
Markets Covered
- Global Procedure Volumes for Neuromodulation Devices – MedPro
- Spinal Cord Stimulation Market - MedCore
- Deep Brain Stimulation Market - MedCore
- Sacral Nerve Stimulation Market - MedCore
- Vagus Nerve Stimulation Market - MedCore
- Gastric Electric Stimulation Market - MedCore
Global Neuromodulation Devices Market Insights
The growing global diabetes epidemic is largely attributed to developing countries adopting a Western diet and a more sedentary lifestyle. Gastroparesis cases caused by diabetes are the rise, driving the gastric electric stimulation market. Neuromodulation therapy is widely considered a second-line treatment, due to its invasiveness and upfront cost compared to pharmaceuticals. Price-sensitive nations with insufficient reimbursement policies will be slow to adopt this therapy.
Overall, the global neuromodulation device market was valued at nearly $4.4 billion in 2019. This is expected to increase over the forecast period at a CAGR of 7.6% to approach $7.3 billion.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- Axonics
- Boston Scientific
- ElectroCore
- IntraPace
- LivaNova
- Medtronic
- Nevro
- Nuvectra
- PINS
- Saluda
- SceneRay
- Stimwave